These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28557009)

  • 1. Drug concentration and antidrug antibodies in patients with psoriasis treated with adalimumab or etanercept.
    Gyldenløve M; Zachariae C; Jensen P; Griehsel H; Ståhle M; Skov L
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e518-e519. PubMed ID: 28557009
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
    Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
    PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis.
    Kui R; Gál B; Gaál M; Kiss M; Kemény L; Gyulai R
    J Dermatol; 2016 Sep; 43(9):1018-23. PubMed ID: 26892625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of adalimumab and etanercept trough levels and drug antibodies in long-term psoriasis treatment: a single-centre cohort study.
    Manriquez J; Alsina-Gibert M
    Clin Exp Dermatol; 2017 Jan; 42(1):14-20. PubMed ID: 27943384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of Antidrug Antibodies in Rheumatoid Arthritis Patients From Argentina Treated With Adalimumab, Etanercept, or Infliximab in a Real-World Setting.
    Maid PJ; Xavier R; Real RM; Pedersen R; Shen Q; Marshall L; Solano G; Borlenghi CE; Hidalgo RP
    J Clin Rheumatol; 2018 Jun; 24(4):177-182. PubMed ID: 29232322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis.
    Mostafa NM; Nader AM; Noertersheuser P; Okun M; Awni WM
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):490-497. PubMed ID: 27545848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab.
    Bissonnette R; Maari C; Barber K; Lynde CW; Vender R
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1576-81. PubMed ID: 25600828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of adalimumab, etanercept and ustekinumab on the expression of psoriasin (S100A7) in psoriatic skin.
    D'Amico F; Trovato C; Skarmoutsou E; Rossi GA; Granata M; Longo V; Gangemi P; Pettinato M; Mazzarino MC
    J Dermatol Sci; 2015 Oct; 80(1):38-44. PubMed ID: 26276441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
    Bandrés Ciga S; Salvatierra J; López-Sidro M; García-Sánchez A; Durán R; Vives F; Raya-Álvarez E
    J Clin Rheumatol; 2015 Apr; 21(3):115-9. PubMed ID: 25807089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence.
    Lombardi G; Perego S; Sansoni V; Diani M; Banfi G; Altomare G
    BMJ Open; 2016 Dec; 6(12):e011941. PubMed ID: 27940624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.
    Mahil SK; Arkir Z; Richards G; Lewis CM; Barker JN; Smith CH
    Br J Dermatol; 2013 Aug; 169(2):306-13. PubMed ID: 23550925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
    Papp KA; Yang M; Sundaram M; Jarvis J; Betts KA; Bao Y; Signorovitch JE
    Value Health; 2018 Jan; 21(1):1-8. PubMed ID: 29304933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
    Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
    PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-TNF biosimilars in psoriasis treatment].
    Viguier M;
    Ann Dermatol Venereol; 2019; 146(6-7):492-496. PubMed ID: 31239173
    [No Abstract]   [Full Text] [Related]  

  • 15. Importance of immunogenicity testing for cost-effective management of psoriasis patients treated with adalimumab.
    Mota F; Neves E; Oliveira JC; Selores M; Torres T
    Acta Dermatovenerol Alp Pannonica Adriat; 2017 Jun; 26(2):33-35. PubMed ID: 28632883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Adalimumab on Gene Expression Profiles of Psoriatic Skin and Blood.
    Chow M; Lai K; Ahn R; Gupta R; Arron S; Liao W
    J Drugs Dermatol; 2016 Aug; 15(8):988-94. PubMed ID: 27538000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria.
    Richter L; Vujic I; Sesti A; Monshi B; Sanlorenzo M; Posch C; Rappersberger K
    J Dtsch Dermatol Ges; 2017 Mar; 15(3):309-317. PubMed ID: 28240404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value.
    Elberdín L; Outeda M; Salvador P; Paradela S; Fernández-Torres RM; Iglesias R; Fonseca E; Martín I
    Int J Clin Pharm; 2016 Oct; 38(5):1142-8. PubMed ID: 27436193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
    Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up.
    Menting SP; van Lümig PP; de Vries AC; van den Reek JM; van der Kleij D; de Jong EM; Spuls PI; Lecluse LL
    JAMA Dermatol; 2014 Feb; 150(2):130-6. PubMed ID: 24352354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.